Crews Bank & Trust Grows Stock Holdings in Abbott Laboratories $ABT

Crews Bank & Trust increased its position in shares of Abbott Laboratories (NYSE:ABT) by 2.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,575 shares of the healthcare product maker’s stock after buying an additional 186 shares during the quarter. Crews Bank & Trust’s holdings in Abbott Laboratories were worth $894,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ABT. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $27,000. Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $28,000. Elequin Capital LP purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of a number of research analyst reports. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Morgan Stanley boosted their target price on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $145.39.

Abbott Laboratories Price Performance

ABT stock opened at $133.05 on Friday. The business’s 50-day moving average is $131.78 and its two-hundred day moving average is $131.28. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $231.56 billion, a P/E ratio of 16.67, a P/E/G ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s payout ratio is presently 29.57%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.